Research

How much does it costs to develop a new drug -- start to finish?

Although the drug industry argues that wholesale prices do not accurately reflect prescription drug costs, this new study finds that rising wholesale prices have, in fact, led to higher out-of-pocket expenses for roughly half of insured patients.

Canada's PMPRB releases a new report reviewing public-coverage of cancer drugs. This is the second in a series of three reports that explore the current gaps and overlaps in Canadian public drug plan formularies. 

Medicaid provides health coverage for millions of Americans, including many with substantial health needs who rely on Medicaid drug coverage both for acute problems and for managing ongoing chronic or disabling conditions.

This new article explores the use of Cost-Effectiveness Analysis (CEA) in drug coverage decisions-making in the United States.

No economy can recover fully from the COVID-19 pandemic until vaccines are equally accessible in all countries.

With more specialty medicines coming to market, the care coordination and financial management associated with high-value therapies is increasing in complexity.

The U.S. GAO has released a new report on international pricing comparisons, analyzing the prices for 20 brand-name drugs in the U.S. for 2020 and comparing them to the publicly available prices for the same drugs in Australia, Canada, and France.

Listen in to hear tips for pharma manufacturers as they develop their market access strategies and prepare to launch physician-administered therapies.

Dan Ollendorf, Ph.D., M.P.H.,of the Center for the Evaluation of Value and Risk in Health at Tufts University Medical Center, is co-author of a new book, The Right Price, A Value-Based Prescription for Drug Costs.

The roles of the public and private sectors in pharmaceutical innovation - a review of the debate over the past 75 years.

New paper mapping out the literature on the attitude toward and intention to purchase generic drugs, and capture insights that can help define and improve promotional strategies for the use of these products. 

ICER publishes white paper evaluating policy options to strengthen FDA’s Accelerated Approval Pathway for prescription drugs.

This paper presents the impact of data exclusivity on the price of pharmaceutical imports.

This paper details and illustrates amortization as a promising method for facilitating market access to gene therapies.